HEPATOCELLULAR CARCINOMA RESECTABLE
Clinical trials for HEPATOCELLULAR CARCINOMA RESECTABLE explained in plain language.
Never miss a new study
Get alerted when new HEPATOCELLULAR CARCINOMA RESECTABLE trials appear
Sign up with your email to follow new studies for HEPATOCELLULAR CARCINOMA RESECTABLE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy aims to shrink liver tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether giving a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) before surgery can improve outcomes for people with liver cancer at high risk of recurrence. About 33 participants will receive the…
Matched conditions: HEPATOCELLULAR CARCINOMA RESECTABLE
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Blood test may spot liver cancer recurrence before scans do
Diagnosis Recruiting nowThis study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can predict if liver cancer will come back after surgery. Researchers will follow 255 patients for two years, taking blood samples regularly to see if the test detects recurrence earli…
Matched conditions: HEPATOCELLULAR CARCINOMA RESECTABLE
Sponsor: Zhujiang Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC